Nectero Secures Category III CPT Codes for EAST System to Treat AAAs

June 12, 2025—Nectero Medical announced that the American Medical Association’s CPT Editorial Panel has approved two Category III CPT codes applicable to Nectero’s endovascular aneurysm stabilization treatment (EAST) system procedure via a percutaneous or open approach. Category III CPT codes are designated for emerging technologies, services, and procedures, noted Nectero.

According to the company, the Nectero EAST system is an investigational, one-time endovascular treatment designed to slow or stabilize the growth of small- to medium-sized abdominal aortic aneurysms (AAAs). It delivers a pentagalloylglucose drug solution directly into the aneurysmal wall via a dual-balloon catheter.

The two newly approved codes will facilitate physician and hospital billing and reimbursement for treatment with the Nectero EAST system in clinical practice, advised the company.

The company stated that the Nectero EAST System is currently being evaluated in the phase 2/3 stAAAble multicenter, randomized clinical trial assessing safety and efficacy in patients with small- to medium-sized AAAs.

In July 2023, Nectero Medical announced that the FDA granted an investigational new drug clearance for the company to initiate the trial. The company commenced the trial in January 2024.

The 1-year follow-up results of the full cohort of patients from the stAAAble trial that were presented in April at the Charing Cross International Symposium 2025, showed a significant reduction in aneurysm diameter growth compared to historical control data, with 91% of patients growing at less than the expected growth rate, advised Nectero.